Arrowstreet Capital Limited Partnership Has $33.88 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Arrowstreet Capital Limited Partnership lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 53.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 101,961 shares of the company’s stock after selling 115,691 shares during the period. Arrowstreet Capital Limited Partnership owned 0.33% of Medpace worth $33,875,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Lindbrook Capital LLC raised its holdings in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC increased its stake in shares of Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. lifted its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after purchasing an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. grew its holdings in Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after buying an additional 30 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MEDP shares. Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective for the company. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $376.30.

Medpace Trading Up 4.5 %

NASDAQ MEDP opened at $311.23 on Thursday. Medpace Holdings, Inc. has a 1-year low of $289.01 and a 1-year high of $459.77. The stock’s 50 day moving average is $333.58 and its two-hundred day moving average is $338.33. The company has a market capitalization of $9.48 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.